250 related articles for article (PubMed ID: 33458327)
1. Focal salvage treatment for radiorecurrent prostate cancer: A magnetic resonance-guided stereotactic body radiotherapy versus high-dose-rate brachytherapy planning study.
Willigenburg T; Beld E; Hes J; Lagendijk JJW; de Boer HCJ; Moerland MA; van der Voort van Zyp JRN
Phys Imaging Radiat Oncol; 2020 Jul; 15():60-65. PubMed ID: 33458327
[TBL] [Abstract][Full Text] [Related]
2. Assessment of HDR brachytherapy-replicating prostate radiotherapy planning for tomotherapy, cyberknife and VMAT.
de Chavez R; Grogan G; Hug B; Howe K; Grigg A; Waterhouse D; Lane J; Glyde A; Brown E; Bydder S; Pryor D; Hargrave C; Charles PH; Hellyer J; Ebert MA
Med Dosim; 2022 Spring; 47(1):61-69. PubMed ID: 34551879
[TBL] [Abstract][Full Text] [Related]
3. Dosimetric comparison of stereotactic MR-guided radiation therapy (SMART) and HDR brachytherapy boost in cervical cancer.
Dincer N; Ugurluer G; Mustafayev TZ; Serkizyan A; Aydin G; Güngör G; Yapici B; Atalar B; Özyar E
Brachytherapy; 2024; 23(1):18-24. PubMed ID: 38000958
[TBL] [Abstract][Full Text] [Related]
4. Dosimetry analyses comparing high-dose-rate brachytherapy, administered as monotherapy for localized prostate cancer, with stereotactic body radiation therapy simulated using CyberKnife.
Fukuda S; Seo Y; Shiomi H; Yamada Y; Ogata T; Morimoto M; Konishi K; Yoshioka Y; Ogawa K
J Radiat Res; 2014 Nov; 55(6):1114-21. PubMed ID: 24957754
[TBL] [Abstract][Full Text] [Related]
5. Treatment planning comparison of high-dose-rate brachytherapy vs. robotic and conventional stereotactic body radiotherapy for ultrahypofractionated treatment of prostate cancer.
Yoshioka Y; Sasamura K; Ito M; Kaneko M; Takahashi T; Anno W; Shimoyachi N; Suzuki J; Okuda T; Kashihara T; Inaba K; Igaki H; Itami J
Phys Imaging Radiat Oncol; 2023 Apr; 26():100445. PubMed ID: 37197153
[TBL] [Abstract][Full Text] [Related]
6. The effect of catheter displacement and anatomical variations on the dose distribution in MRI-guided focal HDR brachytherapy for prostate cancer.
Maenhout M; van der Voort van Zyp JRN; Borot de Battisti M; Peters M; van Vulpen M; van den Bosch M; Moerland MA
Brachytherapy; 2018; 17(1):68-77. PubMed ID: 28579419
[TBL] [Abstract][Full Text] [Related]
7. SBRT focal dose intensification using an MR-Linac adaptive planning for intermediate-risk prostate cancer: An analysis of the dosimetric impact of intra-fractional organ changes.
Brennan VS; Burleson S; Kostrzewa C; Godoy Scripes P; Subashi E; Zhang Z; Tyagi N; Zelefsky MJ
Radiother Oncol; 2023 Feb; 179():109441. PubMed ID: 36549340
[TBL] [Abstract][Full Text] [Related]
8. Second salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer.
Maenhout M; van Vulpen M; Moerland M; Peters M; Meijer R; van den Bosch M; Nguyen P; Frank S; van der Voort van Zyp J
J Contemp Brachytherapy; 2017 Apr; 9(2):161-166. PubMed ID: 28533806
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic Body Radiotherapy Boost with the CyberKnife for Locally Advanced Cervical Cancer: Dosimetric Analysis and Potential Clinical Benefits.
Gao J; Xu B; Lin Y; Xu Z; Huang M; Li X; Wu X; Chen Y
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291951
[TBL] [Abstract][Full Text] [Related]
10. Optimized stereotactic volumetric modulated arc therapy as an alternative to brachytherapy for vaginal cuff boost. A dosimetric study.
Cilla S; Macchia G; Mattiucci G; Ianiro A; Romano C; Buwenge M; Azario L; Valentini V; Deodato F; Morganti AG
Med Dosim; 2020 Winter; 45(4):352-358. PubMed ID: 32565068
[TBL] [Abstract][Full Text] [Related]
11. Dosimetric feasibility of ablative dose escalated focal monotherapy with MRI-guided high-dose-rate (HDR) brachytherapy for prostate cancer.
Hosni A; Carlone M; Rink A; Ménard C; Chung P; Berlin A
Radiother Oncol; 2017 Jan; 122(1):103-108. PubMed ID: 27916416
[TBL] [Abstract][Full Text] [Related]
12. Dosimetric comparison of high-dose-rate brachytherapy and intensity-modulated radiation therapy as a boost to the prostate.
Hermesse J; Biver S; Jansen N; Lenaerts E; Nickers P
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):269-76. PubMed ID: 19775833
[TBL] [Abstract][Full Text] [Related]
13. Dosimetry of local failure with single dose 19 Gy high-dose-rate brachytherapy for prostate cancer.
Armstrong S; Tsang Y; Lowe G; Tharmalingam H; Alonzi R; Ostler P; Hughes R; Hoskin P
Radiother Oncol; 2021 Apr; 157():93-98. PubMed ID: 33493500
[TBL] [Abstract][Full Text] [Related]
14. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations.
Fuller DB; Naitoh J; Lee C; Hardy S; Jin H
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1588-97. PubMed ID: 18374232
[TBL] [Abstract][Full Text] [Related]
15. A dosimetric selectivity intercomparison of HDR brachytherapy, IMRT and helical tomotherapy in prostate cancer radiotherapy.
Hermesse J; Biver S; Jansen N; Lenaerts E; De Patoul N; Vynckier S; Coucke P; Scalliet P; Nickers P
Strahlenther Onkol; 2009 Nov; 185(11):736-42. PubMed ID: 19899007
[TBL] [Abstract][Full Text] [Related]
16.
Adams Q; Hopfensperger KM; Kim Y; Wu X; Flynn RT
Med Phys; 2020 Dec; 47(12):6430-6439. PubMed ID: 33051866
[TBL] [Abstract][Full Text] [Related]
17. Dosimetric benefit of online treatment plan adaptation in stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer.
Fink CA; Buchele C; Baumann L; Liermann J; Hoegen P; Ristau J; Regnery S; Sandrini E; König L; Rippke C; Bonekamp D; Schlemmer HP; Debus J; Koerber SA; Klüter S; Hörner-Rieber J
Front Oncol; 2024; 14():1308406. PubMed ID: 38425342
[TBL] [Abstract][Full Text] [Related]
18. Dosimetric evaluation of Point A and volume-based high-dose-rate plans: a single institution study on adaptive brachytherapy planning for cervical cancer.
Paul AG; Nalichowski A; Abrams J; Paximadis P; Zhuang L; Miller S
J Contemp Brachytherapy; 2018 Jun; 10(3):202-210. PubMed ID: 30038639
[TBL] [Abstract][Full Text] [Related]
19. Development and internal validation of multivariable prediction models for biochemical failure after MRI-guided focal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer.
Willigenburg T; van Son MJ; van de Pol SMG; Eppinga WSC; Lagendijk JJW; de Boer HCJ; Moerland MA; van der Voort van Zyp JRN; Peters M
Clin Transl Radiat Oncol; 2021 Sep; 30():7-14. PubMed ID: 34278009
[TBL] [Abstract][Full Text] [Related]
20. Proof of principle: Applicator-guided stereotactic IMRT boost in combination with 3D MRI-based brachytherapy in locally advanced cervical cancer.
Assenholt MS; Vestergaard A; Kallehauge JF; Mohamed S; Nielsen SK; Petersen JB; Fokdal L; Lindegaard JC; Tanderup K
Brachytherapy; 2014; 13(4):361-8. PubMed ID: 24656732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
